Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: A randomized, double-blinded, placebo-controlled Phase 1b study.
Tafenoquine was recently approved as a chemoprophylaxis for malaria (all species). Its activity against liver and blood stages has been separately characterized in animals but not in humans. In this randomized, double-blinded, placebo-controlled study, 16 malaria naïve, G6PD-normal participants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage P. falciparum. Participants were randomly assigned to either tafenoquine (n=12) or placebo (n=4) and took blinded study medication (single 200 mg dose) on days 1, 2, 3 and 10, followed by intravenous inoculation with ~2,800 P.falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by qPCR. None of the 12 participants who received tafenoquine developed parasitemia while all placebo participants developed parasitemia (p=0.0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy non-immune participants challenged with blood stage P. falciparum.